Big Pharma Companies Acquire Two SoCal Biotech Startups

Keerthi Vedantam

Keerthi Vedantam is a bioscience reporter at dot.LA. She cut her teeth covering everything from cloud computing to 5G in San Francisco and Seattle. Before she covered tech, Keerthi reported on tribal lands and congressional policy in Washington, D.C. Connect with her on Twitter, Clubhouse (@keerthivedantam) or Signal at 408-470-0776.

Big Pharma Companies Acquire Two SoCal Biotech Startups
Photo by Sam Moqadam on Unsplash

Two Southern California biotech startups got swallowed up this week as big pharma benefitted from the record-breaking year of investment in the industry.

Pharmaceutical giant Eli Lilly plucked up a Pasadena startup Protomer Technologies for $1 billion. The company is working on "smart insulin" to treat diabetes.

Another SoCal startup, El Segundo-based Integrity Bio, was acquired by New York drug development company Curia, formerly known as AMRI. Terms of both deals weren't disclosed.

Biotech has been on a tear. Protomer, which last year received an undisclosed funding amount, is one of over a thousand companies who benefited from a banner year in biotech. According to Pitchbook, the industry saw a 60% year-over-year increase in venture capital deal activity in 2020 the largest year-over-year increase ever seen.

Those deals are coming to fruition now, as Protomer and Camarillo-based Integrity Bio, a formulation pharmaceutical upstart, are shedding the need for funding as they get acquired by pharmaceutical companies.

"If Big Pharma wants to start buying assets, more venture capital is going to start pouring into biotech because they know that Big Pharma will be interested in acquiring it down the road," said Bill Bolding, a senior analyst at Provident Healthcare Partners.

Eli Lilly's acquisition of Protomer will give it an even stronger hold on diabetes treatment. Eli Lily's most recent diabetes drug, tirzepatide, outperformed one of its market rivals, and the company is pursuing FDA approval. But glucose-sensing insulin is the next frontier of diabetes treatments, as it has the ability to take into account peoples' unique blood sugar levels.

"With insulin, it's a very complicated drug to use," said Ruth Gimeno, Eli Lilly's vice president of diabetes research. "It's a very efficacious drug, but current insulins are not as safe as we would like them to be. So glucose sensing insulin would just be a complete game changer here."

Curia, a company that formulates and manufactures drugs for other companies, will use Integrity Bio to establish a West Coast presence in the U.S. and get access to the former upstart's slew of clients ranging from startups to Fortune 500 companies. The acquisition is expected to close in the third quarter of 2021.

Subscribe to our newsletter to catch every headline.


Rivian Stock Roller Coaster Continues as Amazon Van Delivery Faces Delays

David Shultz

David Shultz is a freelance writer who lives in Santa Barbara, California. His writing has appeared in The Atlantic, Outside and Nautilus, among other publications.

Rivian Stock Roller Coaster Continues as Amazon Van Delivery Faces Delays
Courtesy of Rivian.

Rivian’s stock lost 7% yesterday on the back of news that the company could face delays in fulfilling Amazon’s order for a fleet of electric delivery vans due to legal issues with a supplier. The electric vehicle maker is suing Commercial Vehicle Group (CVG) over a pricing dispute related to the seats that the supplier promised, according to the Wall Street Journal.

Read more Show less
March Capital's Jamie Montgomery on the Intersection of Innovation and Creativity
March Capital's Jamie Montgomery. Illustration by Dilara Mundy.

When we list the attributes most associated with successful founders, investors, billionaires, and industry leaders, we often think of things like determination, grit, fortitude and even obsessiveness. The winners are the most relentless, the ones who work the hardest, know the most, start the earliest in the morning on four hours of sleep and won’t accept no for an answer.

Read more Show less